PI3K/Akt/mTOR

NIBR-17 is a pan-class I PI3K inhibitor that targets phosphoinositide 3-kinases, key regulators in various signaling pathways. This compound demonstrates significant antitumor activity by effectively inhibiting cell proliferation and survival in cancer models. It is suitable for research applications focused on cancer biology and drug discovery targeting the PI3K/Akt signaling pathway.

Thyroglobulin is a 660 kDa dimeric glycoprotein that serves as a substrate in the synthesis of thyroid hormones, thyroxine (T4) and triiodothyronine (T3). Primarily produced by follicular cells of the thyroid, it also functions in the storage of inactive thyroid hormone forms and iodine in the follicular lumen. In research applications, thyroglobulin has been shown to activate Akt kinase activity in FRTL-5 thyroid cells, making it valuable for studies related to thyroid function and signaling pathways.

Hydroxycitric acid (tripotassium) is a potent activator of the Nrf2, AMPK, and mTOR signaling pathways. It enhances the expression of antioxidant enzymes, elevates glutathione levels, and inhibits ferroptosis, thereby providing protection against oxidative stress and promoting cellular health. This compound is actively engaged in regulating renal and pulmonary vascular functions and is also implicated in the induction of apoptosis in cancer cells through cell cycle arrest and DNA fragmentation. Its multi-target bioactivity makes it a valuable tool in research focused on oxidative stress, cancer biology, and metabolic regulation.

(+)−Theta-cypermethrin is a stereoisomer of cypermethrin that functions as a selective binder to AKT1, SRC, STAT3, and epidermal growth factor receptor (EGFR). This compound is known to penetrate the blood-brain barrier, leading to alterations in the amplitude of delayed rectifier potassium channel currents and significant shifts in the activation and inactivation curves at elevated concentrations. Additionally, (+)-Theta-cypermethrin induces abnormal electrical activity in rat hippocampal neurons and is associated with chronic respiratory system damage and neurotoxicity. It serves as a valuable tool for research into signal transduction pathways and neuropharmacology.

NVP-BBD130 is a potent dual inhibitor of PI3K and mTOR, functioning through ATP-competitive mechanisms. This compound demonstrates significant stability and provides effective oral bioavailability. Additionally, NVP-BBD130 serves as a click chemistry reagent due to its alkyne group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its versatility makes it suitable for various research applications in cancer therapy and biochemical signaling pathways.

Zandelisib is a selective, orally active, non-covalent inhibitor of PI3Kδ. It effectively inhibits AKT phosphorylation and suppresses downstream signaling pathways, making it a valuable tool in cancer research. Zandelisib is particularly relevant for studying malignancies such as relapsed or refractory B-cell lymphoma, providing insights into tumor behavior and therapeutic response.

Copanlisib-NH is a selective ligand for the PI3Kα/δ isoforms, making it a valuable tool in targeted protein degradation studies. This compound serves as a ligand in the development of PROTACs aimed at degrading PI3Kα/δ proteins, facilitating research on mechanisms of resistance and cellular pathways in oncology. Notably, Copanlisib-NH is applicable in breast cancer research, offering insights into therapeutic strategies that exploit the PI3K signaling pathway.

NUAK1-IN-3 is a selective inhibitor of NUAK1 with a high potency, exhibiting an IC50 of 0.49 nM. It also demonstrates inhibitory activity against NUAK2 and JAK3 with IC50 values of 265 nM and 225 nM, respectively. This compound disrupts the NUAK1-MYPT1 signaling pathway, leading to reduced MYPT1 phosphorylation and inhibition of proliferation, migration, and invasion in triple-negative breast cancer cells. Additionally, NUAK1-IN-3 counteracts TGF-β1-induced epithelial-mesenchymal transition effects by modulating critical markers such as Snail, N-cadherin, and E-cadherin. It holds potential for exploring therapeutic strategies for triple-negative breast cancer.

SGK1-IN-8 is a potent inhibitor of SGK1 and GSK3β, exhibiting an IC50 of 0.11 μM against human SGK1 and 3.39 μM against human GSK3β. This compound effectively inhibits the catalytic activities of both SGK1 and GSK3β, leading to a reduction in the phosphorylation of the TAU protein at the Ser214 site. SGK1-IN-8 is utilized in research focused on Alzheimer's disease and related neurodegenerative disorders.